Skip to main content
Fig. 4 | Cost Effectiveness and Resource Allocation

Fig. 4

From: A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore

Fig. 4

Tornado diagram for ICER based on one-way sensitivity analysis. *Dominant, ~ Dominated. BAT, best available therapy; DoR, duration of response; DoT, duration of treatment; ICER, incremental cost-effectiveness ratio; NR, non-responder; ORR, overall response rate/overall responder; OS, overall survival; QALY, quality-adjusted life year; SD, standard deviation; SGD, Singapore dollar

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us